Givosiran (Givlaari)

Givosiran (Givlaari) is covered for the treatment of adults (≥18 years) with an FDA‑approved diagnosis of acute hepatic porphyria (AHP) and is not covered for patients under 18 or for non‑FDA‑approved indications. Approval requires prescription by or consultation with a gastroenterologist, hepatologist, or AHP specialist, documentation of diagnosis and age, adherence to applicable safety criteria, and the recommended dosing of 2.5 mg/kg subcutaneously once monthly.

"Treatment of adults with acute hepatic porphyria (AHP)."

Sign up to see full coverage criteria, indications, and limitations.